4.8 Review

Liver cirrhosis

Journal

LANCET
Volume 371, Issue 9615, Pages 838-851

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(08)60383-9

Keywords

-

Funding

  1. NCCIH NIH HHS [U01 AT003571-01, U01 AT003571, U01 AT003571-02] Funding Source: Medline
  2. NIAID NIH HHS [U19 AI066313-029001, U19 AI066313-049001, U19 AI066313-030003, U19 AI066313-020003, U19 AI066313-039001, U19 AI066313-010003, U19 AI066313-019001, U19 AI066313-040003] Funding Source: Medline
  3. NIDDK NIH HHS [R21 DK076873-01A1, 1 R21 DK076873-01A1] Funding Source: Medline
  4. PHS HHS [U19 A1 066313] Funding Source: Medline

Ask authors/readers for more resources

Cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, which leads to portal hypertension and end-stage liver disease. Recent advances in the understanding of the natural history and pathophysiology of cirrhosis, and in treatment of its complications, have resulted in improved management, quality of life, and life expectancy of patients. Liver transplantation remains the only curative option for a selected group of patients, but pharmacological treatments that can halt progression to decompensated cirrhosis or even reverse cirrhosis are currently being developed. This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available